Progenitor Eosinophil Immunophenotyping Panel (PEIP)

Our Progenitor Eosinophil Immunophenotyping Panel (PEIP) identifies and quantifies eosinophil progenitor cells in peripheral blood, providing a minimally-invasive approach to monitoring disease activity. This panel is crucial for understanding and managing eosinophilic disorders effectively. Here are key aspects of our Progenitor Eosinophil Immunophenotyping Panel (PEIP):

1. Identification of Eosinophil Progenitor Cells:
   • The PEIP is designed to identify eosinophil progenitor (EOP) cells in the peripheral blood, which are indicative of eosinophilic inflammation.
   • Markers include lineage: (CD2, CD3, CD4, CD7, CD8, CD10, CD11b, CD14, CD19, CD20, CD56, CD235a), CD45RA, CD125, CD123, CD38, CD34.
2. Quantification of EOP Cells:
   • This panel provides precise quantification of EOP cells, offering detailed insights into the extent of eosinophilic activity.
   • Reportable markers include: CD45RA-CD43High+ % of all cells, CD45RA-CD34High+ Absolute Number (Cells/mL Blood), EOP cells-% of all cells, EOP cells-Absolute Number (Cells/mL Blood), Ratio of EOP cells: CD45RA-CD43High+, % of all Cells, Absolute number.
3. Monitoring Disease Activity:
   • The PEIP is essential for monitoring the activity of eosinophilic disorders, allowing for timely adjustments to treatment plans.
   • Regular monitoring helps in assessing the effectiveness of therapies and disease progression.
4. Minimally-Invasive Approach:
   • The PEIP offers a minimally-invasive alternative to more invasive procedures, making it easier and safer for patients.
   • This approach reduces patient discomfort and risk while providing valuable diagnostic information.
5. Understanding Inflammatory Mechanisms:
   • By identifying and quantifying EOP cells, the PEIP provides insights into the inflammatory mechanisms underlying eosinophilic disorders.
   • This understanding helps in developing targeted therapies that address the root cause of inflammation.
6. Comprehensive Analysis:
   • All reports from the PEIP include a comprehensive analysis relevant to the individual patient’s condition.
   • Our consultative insights help clinicians make informed decisions about patient care, improving treatment outcomes.

By utilizing the Progenitor Eosinophil Immunophenotyping Panel (PEIP), we provide a detailed and minimally-invasive method for identifying and quantifying eosinophil progenitor cells. This panel is a vital tool for monitoring disease activity and guiding effective treatment plans, ultimately enhancing patient care and quality of life.